Quick Answer
Selenium Thyroid Function Meta-Analysis has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Combination therapy significantly reduced TSH levels compared with Sel monotherapy (SMD -1.26; 95% CI -1.51 to -1.00; p 2 = 0%), and TSA suggested that this finding may be robust, although the evidence is limited by the small number of studies.
Key Takeaways
- 01Combination therapy significantly reduced TSH levels compared with Sel monotherapy (SMD -1.26; 95% CI -1.51 to -1.00; p 2 = 0%), and TSA suggested that this finding may be robust, although the evidence is limited by the small number of studies. [Stanchev P (2026)]
- 02TgAb levels were also significantly reduced (SMD -0.51; 95% CI -0.78 to -0.24; p 2 = 0%); however, TSA indicated a potential risk of type I error. [Stanchev P (2026)]
- 03Conclusions : MI combined with Sel was associated with a significant reduction in TSH levels compared with Sel alone in patients with HT and subclinical hypothyroidism, suggesting a potential therapeutic benefit. [Stanchev P (2026)]
- 04Introduction : Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism in iodine-sufficient regions and often presents with subclinical hypothyroidism. [Stanchev P (2026)]
The current Migaku evidence database contains 2 reusable source documents for Selenium Thyroid Function Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Combination therapy significantly reduced TSH levels compared with Sel monotherapy (SMD -1.26; 95% CI -1.51 to -1.00; p 2 = 0%), and TSA suggested that this finding may be robust, although the evidence is limited by the small number of studies. [Stanchev P (2026); evidence level 1]
- TgAb levels were also significantly reduced (SMD -0.51; 95% CI -0.78 to -0.24; p 2 = 0%); however, TSA indicated a potential risk of type I error. [Stanchev P (2026); evidence level 1]
- Conclusions : MI combined with Sel was associated with a significant reduction in TSH levels compared with Sel alone in patients with HT and subclinical hypothyroidism, suggesting a potential therapeutic benefit. [Stanchev P (2026); evidence level 1]
- Introduction : Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism in iodine-sufficient regions and often presents with subclinical hypothyroidism. [Stanchev P (2026); evidence level 1]
- Although biochemical euthyroidism can usually be achieved with appropriate hormone therapy, a subset of patients continues to report persistent symptoms such as fatigue, cognitive difficulty, weight changes, and reduced quality of life (QOL), even after biochemical optimization. [Personius L (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources